Literature DB >> 27231154

Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to a κ-Opioid Agonist in THC-Treated Mice.

Girish R Chopda1, Viraj Parge2, Ganesh A Thakur2, S John Gatley2, Alexandros Makriyannis2, Carol A Paronis1.   

Abstract

Daily treatment with cannabinoids results in tolerance to many, but not all, of their behavioral and physiologic effects. The present studies investigated the effects of 7-day exposure to 10 mg/kg daily of Δ(9)-tetrahydrocannabinol (THC) on the diuretic and antinociceptive effects of THC and the synthetic cannabinoid AM4054. Comparison studies determined diuretic responses to the κ-opioid agonist U50,488 and furosemide. After determination of control dose-response functions, mice received 10 mg/kg daily of THC for 7 days, and dose-response functions were re-determined 24 hours, 7 days, or 14 days later. THC and AM4054 had biphasic diuretic effects under control conditions with maximum effects of 30 and 35 ml/kg of urine, respectively. In contrast, antinociceptive effects of both drugs increased monotonically with dose to >90% of maximal possible effect. Treatment with THC produced 9- and 7-fold rightward shifts of the diuresis and antinociception dose-response curves for THC and, respectively, 7- and 3-fold rightward shifts in the AM4054 dose-response functions. U50,488 and furosemide increased urine output to >35 ml/kg under control conditions. The effects of U50,488 were attenuated after 7-day treatment with THC, whereas the effects of furosemide were unaltered. Diuretic effects of THC and AM4054 recovered to near-baseline levels within 14 days after stopping daily THC injections, whereas tolerance to the antinociceptive effects persisted longer than 14 days. The tolerance induced by 7-day treatment with THC was accompanied by a 55% decrease in the Bmax value for cannabinoid receptors (CB1). These data indicate that repeated exposure to THC produces similar rightward shifts in the ascending and descending limbs of cannabinoid diuresis dose-effect curves and to antinociceptive effects while resulting in a flattening of the U50,488 diuresis dose-effect function.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27231154      PMCID: PMC4959092          DOI: 10.1124/jpet.116.232132

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

1.  Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo.

Authors:  S J Gatley; R Lan; N D Volkow; N Pappas; P King; C T Wong; A N Gifford; B Pyatt; S L Dewey; A Makriyannis
Journal:  J Neurochem       Date:  1998-01       Impact factor: 5.372

2.  Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration.

Authors:  David R Maguire; Wenjuan Yang; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2013-03-27       Impact factor: 4.030

3.  Cannabinoid and kappa opioid receptors reduce potassium K current via activation of G(s) proteins in cultured hippocampal neurons.

Authors:  R E Hampson; J Mu; S A Deadwyler
Journal:  J Neurophysiol       Date:  2000-11       Impact factor: 2.714

4.  Δ(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice.

Authors:  Carol A Paronis; Spyros P Nikas; Vidyanand G Shukla; Alexandros Makriyannis
Journal:  Behav Pharmacol       Date:  2012-12       Impact factor: 2.293

5.  Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.

Authors:  F Fan; D R Compton; S Ward; L Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1994-12       Impact factor: 4.030

6.  The time course and significance of cannabis withdrawal.

Authors:  Alan J Budney; Brent A Moore; Ryan G Vandrey; John R Hughes
Journal:  J Abnorm Psychol       Date:  2003-08

7.  Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice.

Authors:  P B Smith; S P Welch; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1994-03       Impact factor: 4.030

8.  Large receptor reserve for cannabinoid actions in the central nervous system.

Authors:  A N Gifford; M Bruneus; S J Gatley; R Lan; A Makriyannis; N D Volkow
Journal:  J Pharmacol Exp Ther       Date:  1999-02       Impact factor: 4.030

9.  Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study.

Authors:  M Herkenham; A B Lynn; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  J Neurosci       Date:  1991-02       Impact factor: 6.167

10.  Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine.

Authors:  Javier Garzón; Elena de la Torre-Madrid; María Rodríguez-Muñoz; Ana Vicente-Sánchez; Pilar Sánchez-Blázquez
Journal:  Mol Pain       Date:  2009-03-10       Impact factor: 3.395

View more
  4 in total

1.  Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538.

Authors:  Carol A Paronis; Girish R Chopda; Kiran Vemuri; Ani S Zakarian; Alexandros Makriyannis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2018-01-08       Impact factor: 4.030

2.  Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice.

Authors:  Catheryn D Wilson; Sherrica Tai; Laura Ewing; Jasmine Crane; Taylor Lockhart; Ryochi Fujiwara; Anna Radominska-Pandya; William E Fantegrossi
Journal:  J Pharmacol Exp Ther       Date:  2018-11-12       Impact factor: 4.030

3.  Stimulation of diuresis and natriuresis by renomedullary infusion of a dual inhibitor of fatty acid amide hydrolase and monoacylglycerol lipase.

Authors:  Ashfaq Ahmad; Zdravka Daneva; Guangbi Li; Sara K Dempsey; Ningjun Li; Justin L Poklis; Aron Lichtman; Pin-Lan Li; Joseph K Ritter
Journal:  Am J Physiol Renal Physiol       Date:  2017-08-02

Review 4.  The nephrologist's guide to cannabis and cannabinoids.

Authors:  Joshua L Rein
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-03       Impact factor: 3.416

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.